PATENT CLAIM ANALYSIS

Application Number: 16007340
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2018-10
Patent Classification: ["514", "330000"]

Abstract:
The present invention relates to inhibitors of C5a activity and their use in the treatment of cutaneous, neutrophilic, inflammatory diseases in a subject.

Claim (Index 13):
The method of  claim 12 , wherein the agent that inhibits C5a activity is an antibody or an antigen-binding fragment thereof that competes with the Eculizumab antibody, ALXN1210 antibody, ALXN5500 antibody, LFG316 antibody, or an antigen-binding fragment thereof, for binding to C5.

Metadata:
- Claim Count in Document: 40.0
- Percentile: 94.0
- Lexical Diversity: 1.13043
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['14729865', '15127676', '13512334', '12011058', '10222464']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7626602729302776
- 35 USC 102 Novelty (BERT): 0.524365705394973
- Combined Prediction Score: 0.7388308161767472
- Mean Citation Score: 297.5676400000001
- Max Citation Score: 302.56268
- Similarity Product: 213.1259281545592

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test